Classifying treatment effects for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This study looks at how well different treatments work for people with advanced liver cancer. It may help doctors better understand which treatments are most effective for patients like you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer that has spread or cannot be removed with surgery.
- You do not have severe diabetes, heart failure, or serious liver or kidney problems.
- You have never been diagnosed with schizophrenia.
- You have not had another type of cancer or found a tumor that spread to your liver from somewhere else.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests immunotherapy-based combinations for liver cancer. It may help if your doctor thinks this treatment could benefit you.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This study compares two treatment approaches for advanced liver cancer that has spread within the liver but not to other parts of the body. Both treatments combine chemotherapy delivered directly to the liver with immunotherapy drugs to help your immune system fight the cancer.
This study is testing whether combining targeted therapy with immunotherapy can help people with advanced liver cancer that cannot be surgically removed. The goal is to see if this combination treatment is safe and effective.
This trial studies how liver cancer changes during immunotherapy and looks for biological markers that may predict treatment response. It helps doctors understand why some patients benefit more from treatment.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.